Polyrizon Ltd. is a biotechnology company focused on developing innovative solutions for the medical and healthcare sectors, particularly in the realm of drug delivery and tissue protection. The company is at the forefront of creating unique polymer-based products designed to enhance the efficacy and safety of therapeutic applications. By leveraging advanced materials science, Polyrizon aims to address various clinical challenges, potentially improving patient outcomes through its proprietary technologies. Their research emphasizes enhancing the biocompatibility and performance of medical treatments, particularly in the fields of wound care, vaccination, and regenerative medicine. Read More
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Peraso (NASDAQ: PRSO) The Future of mmWave Technology as Takeover Bid Underscores Surging Confidence – More Stocks Inside The unsolicited acquisition offer from Mobix Labs to acquire Peraso Inc. (NASDAQ: PRSO) is sending waves through the tech investment community. More than a financial move, the proposal is a strategic endorsement of Peraso’s mmWave leadership, a technology that continues to gain relevance in defense and commercial sectors. The offer comes as Peraso posts a Q1 revenue of $3.8 million , with mmWave sales already surpassing 2024 totals. Recent contract wins—including a $3.6 million FWA order and military-grade 60GHz system shipments —point to a business in acceleration mode, not desperation. The bid may ultimately be seen as external validation of Peraso’s growth trajectory and IP moat .
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Ra’anana, Israel, July 22, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product’s potential as a barrier-forming treatment for allergic rhinitis.
Following a surge of 52.47% during regular trading session on Tuesday, Polyrizon Ltd (NASDAQ: PLRZ) witnessed a dip of 12.02% during pre-market trading on Wednesday.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Raanana, Israel, July 15, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced that it has received a notification letter from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request for the continued listing of its securities on the Nasdaq Capital Market.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based Trap & Target (T&T) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated that Polyrizon’s hydrogel formulation achieves targeted deposition in the upper regions of the nasal cavity—critical for central nervous system (CNS) drug delivery.
